Document Detail


Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension.
MedLine Citation:
PMID:  16292989     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Sitaxsentan is an orally active, selective endothelin-A receptor antagonist that may benefit patients with pulmonary arterial hypertension by blocking the vasoconstrictive effects of endothelin-A receptors, while maintaining the vasodilator and endothelin-1 clearance functions of the endothelin-B receptors. In its first randomized, placebo-controlled study, sitaxsentan improved exercise capacity assessed by the 6-min walk test, New York Heart Association functional class, cardiac index and pulmonary vascular resistance in New York Heart Association Class II, III and IV patients with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension related to connective tissue disease or congenital heart disease. Although doses of 100 and 300 mg once daily demonstrated equivalent efficacy, the lower dose had a better safety profile. Additional studies are ongoing to assess the relative safety and efficacy of 50 and 100 mg once-daily dosing. The most common side effects include rhinitis, headache, peripheral edema, chest pain, nausea, constipation, increased prothrombin time/international normalized ratio (in patients on warfarin), flushing and insomnia. As with other endothelin receptor antagonists, increases in hepatic transaminases have been observed with sitaxsentan. Initial studies using the selective oral endothelin-A receptor antagonist sitaxsentan in pulmonary arterial hypertension patients have revealed a favorable risk-benefit therapeutic profile with the 100 mg once-daily dose.
Authors:
Allison C Widlitz; Robyn J Barst; Evelyn M Horn
Related Documents :
24891789 - Anterolateral thigh twin free flaps from a single donor site-a modification based on th...
20347789 - Heart failure and pulmonary hypertension.
17494809 - Pulmonary hypertension due to a retained totally implantable venous access device fragm...
9363069 - Pulmonary hypertension and cor pulmonale.
16412689 - Pulmonary hypertension due to isolated metastatic squamous cell carcinoma thromboemboli.
23022199 - A case of an extremely rare unilateral subscapular trunk and axillary artery variation ...
21256339 - Primary complete repair of partial double aortic arch and kommerell diverticulum.
2517719 - The effect of alpha-tocopherol and intal on heart capillary bed and lipid peroxide oxid...
15942089 - Is stroke a paradoxical embolism in patients with patent foramen ovale?
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  3     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-11-18     Completed Date:  2006-07-20     Revised Date:  2008-06-05    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  985-91     Citation Subset:  IM    
Affiliation:
Pulmonary Hypertension Center, Columbia University College of Physicians and Surgeons, BHN 2-255, New York, NY 10032, USA. aw317@columbia.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic
Humans
Hypertension, Pulmonary / drug therapy*
Isoxazoles / adverse effects,  therapeutic use*
Receptors, Endothelin / antagonists & inhibitors*
Thiophenes / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Isoxazoles; 0/Receptors, Endothelin; 0/Thiophenes; 0/sitaxsentan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ankyrin-B coordinates the Na/K ATPase, Na/Ca exchanger, and InsP3 receptor in a cardiac T-tubule/SR ...
Next Document:  Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety.